DXM + Linezolid

https://dxm-atlas.org/en/interactions/linezolid/

Compare

Key points for this combination

Weak, reversible inhibition of monoamine oxidase (MAO), an enzyme that breaks down monoamines. The review reports negative findings from controlled DXM testing at therapeutic exposure. These findings apply to the tested conditions. Concern under other conditions comes from the mechanism. AUVELITY labeling contraindicates use together [2, 39, 40].

General concepts in this text

Enzyme

A protein that helps chemical transformations in cells.

A transformation can build or break down a substance.

Sources: Enzyme

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase

Monoamines

A group of substances formed in living organisms; several act as chemical messengers between nerve cells.

Examples include serotonin, dopamine and norepinephrine.

Sources: Monoamines

How well is this understood?

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: medium

Confidence in direct human evidence involving DXM: medium

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
The study did not find the effect it tested for. Result in the interaction card

How to read ratings and study limits

How do the substances interact?

How can the effects add up?

Mechanism: MAO — Monoamine oxidase
ⓘ

MAO — monoamine oxidase

An enzyme involved in breaking down serotonin.

Breakdown and reuptake are different processes.

Sources: MAO — monoamine oxidase
  1. Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations. Finding below: Finding [39]
  2. Current linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].
Serotonin toxicity

A condition caused by excessive serotonin activity in the nervous system.

Also called serotonin syndrome. Features can include tremor and involuntary muscle jerks, raised body temperature, a fast heartbeat, agitation or confusion.

Sources: Serotonin toxicity

In the glossary

What remains unknown?

These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.

Sources

Check the review’s wording

Mild reversible MAO inhibition; negative controlled DXM interaction findings at therapeutic exposure. Concern at other exposures is mechanistic; AUVELITY contraindicates coadministration [2, 39, 40]

Combination row in the review: MAO — Monoamine oxidase

Evidence and sources

Research publication

[39] · Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr · 2001

Finding [39]

What was found?

Hendershot and colleagues’ controlled healthy-volunteer study found no significant blood-pressure effect with DXM and only a small decrease in DXO concentrations.

What limits this finding?

These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.

Scientific review: Linezolid and intravenous methylene blue

Prescribing information

[40] · LINEZOLID prescribing information

Finding [40]

What does the label say?

Current linezolid labeling also reports no observed serotonin-syndrome signs in the studied DXM combination [39, 40].

What does this label information cover?

These are negative results for the measures studied at therapeutic exposures. Their scope is limited to the study conditions.

Scientific review: Linezolid and intravenous methylene blue

Related entries

Reference

Open the source and related combinations →